Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4226MR)

This product GTTS-WQ4226MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4226MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7864MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ7225MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ11906MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ9518MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ12640MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ3914MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ10659MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ11766MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-1308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW